Amneal Pharmaceuticals, Inc.
AMRXNASDAQHealthcare● Active
$13.75
+$0.23(+1.70%)
Market Cap$4.4B
P/E Ratio—
52W High$15.42
52W Low$7.07
Amneal Pharmaceuticals, Inc. (AMRX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AMRX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B |
| Cost of Revenue | $1.88B | $1.77B | $1.53B | $1.42B | $1.32B |
| Gross Profit | $1.14B | $1.02B | $0.86B | $0.79B | $0.77B |
| Gross Margin %(computed) | 37.63% | 36.52% | 36.09% | 35.78% | 36.73% |
| Operating Expenses | |||||
| R&D Expenses | $0.19B | $0.19B | $0.19B | $0.21B | $0.21B |
| G&A Expenses | $0.00B | $0.44B | $0.42B | $0.38B | $0.00B |
| Total Operating Expenses | $0.71B | $0.77B | $0.66B | $0.89B | $0.62B |
| Operating Income | $0.42B | $0.25B | $0.20B | ($0.09B) | $0.15B |
| Operating Margin %(computed) | 14.02% | 8.92% | 8.54% | -4.29% | 7.29% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.16B | $0.00B |
| Interest Expense | $0.24B | $0.26B | $0.21B | $0.16B | $0.14B |
| Income Before Tax | $0.14B | ($0.06B) | ($0.04B) | ($0.25B) | $0.03B |
| Income Tax Expense | $0.01B | $0.02B | $0.01B | $0.01B | $0.01B |
| Net Income | $0.07B | ($0.12B) | ($0.08B) | ($0.13B) | $0.01B |
| Net Margin %(computed) | 2.39% | -4.18% | -3.51% | -5.88% | 0.51% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.23 | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Wtd Avg Shares | 0.31B | 0.31B | 0.17B | 0.15B | 0.15B |
| EBITDA | $0.60B | $0.44B | $0.50B | $0.44B | $0.40B |
| EBITDA Margin %(computed) | 20.00% | 15.74% | 20.92% | 19.90% | 19.16% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Amneal Pharmaceuticals, Inc. data
About Amneal Pharmaceuticals, Inc. (AMRX) Income Statement
Amneal Pharmaceuticals, Inc. (AMRX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AMRX reported revenue of $3.02B, gross profit of $1.14B (gross margin 37.63%), and net income of $0.07B — a net profit margin of 2.39%.
Frequently asked questions
AMRX · 4 questionsAmneal Pharmaceuticals, Inc. (AMRX) reported revenue of $3.02B for 2025, up 8.0% year-over-year.
AMRX revenueAMRX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08